Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2020-01-28, Stock:LLY, The news for the past five days is as follows:
2020-01-21: NEWS1: Pharma Company Buybacks: Do They Really Benefit Shareholders?.NEWS2: Governor Cooper Announces over 460 Jobs in Durham as Eli Lilly and Company Selects North Carolina for Major Pharmaceutical Plant.NEWS3: Eli Lilly and Company taps Durham for 450+ jobs, new facility.NEWS4: Pharma giant Eli Lilly and Company taps Durham for 450+ jobs.
2020-01-22: NEWS1: Steven Cohen's Point72 Piles Into Menlo Therapeutics.NEWS2: Durham is on a winning streak for new jobs, but will it continue?.NEWS3: Health stocks reverse coronavirus gains as one analyst says the market is overreacting.NEWS4: Top Stock Analyst Reports for Pfizer, Wells Fargo & SAP.NEWS5: Glaxo's Multiple Myeloma Candidate Gets FDA's Priority Review.NEWS6: Should First Trust Capital Strength ETF (FTCS) Be on Your Investing Radar?.
2020-01-23: NEWS1: The Zacks Analyst Blog Highlights: Pfizer, Wells Fargo, SAP, salesforce.com and Eli Lilly.
2020-01-24: NEWS1: Eli Lilly (LLY) Dips More Than Broader Markets: What You Should Know.NEWS2: Drug Stocks Slide as Never-Ending Political Worry Gathers Steam.NEWS3: After losing out on big prospect, O'Neill's Discovery Labs takes on cell-gene therapy manufacturing.NEWS4: J&J's Stelara Gets EU Nod for Plaque Psoriasis in Children.NEWS5: Anat Hakim to join Lilly as General Counsel.
2020-01-27: NEWS1: US FDA approves only triple-combination tablet with Jardiance® for adults with type 2 diabetes.NEWS2: Eli Lilly Trading Near Top Of Buy Zone With Earnings On Tap.NEWS3: Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?.NEWS4: Lilly (LLY) to Report Q4 Earnings: What's in the Cards?.NEWS5: Lilly and Incyte Announce Top-Line Results from Phase 3 Study (BREEZE-AD4) of Oral Selective JAK Inhibitor Baricitinib in Combination with Topical Corticosteroids in Patients with Moderate to Severe Atopic Dermatitis Not Controlled with Cyclosporine.

Answer: Rise